DASATINIB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dasatinib, and when can generic versions of Dasatinib launch?
Dasatinib is a drug marketed by Apotex and is included in two NDAs.
The generic ingredient in DASATINIB is dasatinib. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dasatinib profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DASATINIB?
- What are the global sales for DASATINIB?
- What is Average Wholesale Price for DASATINIB?
Summary for DASATINIB
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 139 |
Clinical Trials: | 360 |
Patent Applications: | 4,294 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DASATINIB |
DailyMed Link: | DASATINIB at DailyMed |
![DASATINIB drug patent expirations Drug patent expirations by year for DASATINIB](/p/graph/s/t/DASATINIB-patent-expirations.png)
Recent Clinical Trials for DASATINIB
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fernando De la Garza Salazar | Phase 2 |
Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
Institut Paoli-Calmettes | Phase 2 |
Medical Subject Heading (MeSH) Categories for DASATINIB
Anatomical Therapeutic Chemical (ATC) Classes for DASATINIB
US Patents and Regulatory Information for DASATINIB
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apotex | DASATINIB | dasatinib | TABLET;ORAL | 202103-001 | Jun 10, 2016 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | DASATINIB | dasatinib | TABLET;ORAL | 203180-001 | Nov 23, 2021 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | DASATINIB | dasatinib | TABLET;ORAL | 202103-002 | Jun 10, 2016 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | DASATINIB | dasatinib | TABLET;ORAL | 202103-003 | Jun 10, 2016 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | DASATINIB | dasatinib | TABLET;ORAL | 203180-002 | Nov 23, 2021 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | DASATINIB | dasatinib | TABLET;ORAL | 202103-004 | Jun 10, 2016 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |